The HIV-1 specific T cell response is initially effective but in the face of HIV-1's phenomenal ability to alter its sequence and escape from immune pressure, loss of CD4 T cell help and chronic antigen, the response becomes """"""""exhausted"""""""" and no longer can longer control HIV-1 replication. Overcoming or reversing T cell exhaustion is likely going to be an important part of any successful HIV-1 immunotherapy, but how to do this is currently not clear. We propose to develop and combine two exciting approaches to restore HIV-1 specific immunity. The first involves using high affinity HIV-1 specific TCRs to redirect the immune response toward HIV-1. This approach has the potential to reset the HIV-1 specific exhaustion clock and to re-establish control of HIV-1 replication. Our preliminary data indicates the high affinity TCRs confer a more pronounced polyfunctional T cell response, the ability to control HIV-1 replication at low effector to target ratios and the ability to recognize common SL9-escape mutants. Here, we propose to extend these to studies to in vivo models and mechanistic studies. The second approach is to render these HIV-1 specific T cells resistant to the exhaustion differentiation pathway by targeting PD-1 expression. To do this we will use zinc finger nucleases to permanently disrupt PD-1 expression. The advantage of this approach over the systematic delivery of blocking Abs is that loss of PD-1 expression is restricted to the HIV-1 specific T cells that are being infused. Thus, the potential for autoimmunity is reduced. We propose to achieve our goal of reinvigorating the HIV-1 specific immune response through three related and coordinated specific aims: 1) Develop and characterize a lead PD-1 specific ZFN;2 Determine how PD-1 deficiency affects the HIV-1 specific T cell response;3) Perform in vivo, pre-clinical experiments to determine whether PD-1 deficient HIV-1 specific T cells are superior at controlling HIV-1 replication. These studies will provide the basis and rationale to test this approach in humans and hopefully lead to clinical tools that successfully control of HIV-1 replication in the absence of HAART.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Richardson, Max W; Guo, Lili; Xin, Frances et al. (2014) Stabilized human TRIM5? protects human T cells from HIV-1 infection. Mol Ther 22:1084-1095
Zhang, Qian; Wang, Hong Yi; Wei, Fang et al. (2014) Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol 192:2913-9
Moon, Edmund K; Wang, Liang-Chuan; Dolfi, Douglas V et al. (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 20:4262-73
Zhang, Qian; Wei, Fang; Wang, Hong Yi et al. (2013) The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. Am J Pathol 183:1971-80
Wei, Fang; Zhong, Shi; Ma, Zhengyu et al. (2013) Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A 110:E2480-9
Thakral, Deepshi; Coman, Maria M; Bandyopadhyay, Arunima et al. (2013) The human CD8? M-4 isoform dominant in effector memory T cells has distinct cytoplasmic motifs that confer unique properties. PLoS One 8:e59374
Maier, Dawn A; Brennan, Andrea L; Jiang, Shuguang et al. (2013) Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 24:245-58
Martin, Sunil; Saha, Bhaskar; Riley, James L (2012) The battle over mTOR: an emerging theatre in host-pathogen immunity. PLoS Pathog 8:e1002894
Richardson, Max W; Jadlowsky, Julie; Didigu, Chuka A et al. (2012) Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol 189:3815-21
Amarnath, Shoba; Costanzo, Carliann M; Mariotti, Jacopo et al. (2010) Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol 8:e1000302